SELFCARE OTC ELECTROCHEMICAL BLOOD GLUCOSE MONITOR KIT 510(k) PENDING AT FDA; COMPANY ANTICIPATES $29.2 MIL. IN NET PROCEEDS FROM INITIAL PUBLIC OFFERING
This article was originally published in The Gray Sheet
Executive Summary
Selfcare submitted a 510(k) in late May for its over-the-counter electrochemical blood glucose monitor kit, the firm says. The test kit will be marketed by Johnson & Johnson subsidiary LifeScan under a November 1995 worldwide alliance with Waltham, Massachusetts-based Selfcare. LifeScan, the leader in the OTC blood glucose test market, does not currently market an electrochemical test. Selfcare outlines plans for the product in a May 17 preliminary prospectus for an initial public offering.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.